23 results about "Lipid composition" patented technology

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

This invention discloses a lipid composition, stock solution, preparation method, preparation system, and application for preparing broad-spectrum solvent-compatible liposomes. The lipid composition consists of HSPC, cholesterol, octadecylamine, and vitamin E polyethylene glycol succinate in specific proportions; it is dissolved in an aqueous organic solvent (such as ethanol) to form a lipid stock solution; the preparation system employs a three-channel intelligent control pump; in the preparation method, the above-mentioned lipid stock solution, an aqueous phase containing the target components (which can be pure water to 40% organic solvent-water solution), and a blank aqueous phase are injected into a microfluidic chip to generate a liposome dispersion, which is then purified. This invention overcomes the limitation of solvent polarity on liposome preparation, enabling the stable preparation of high-quality liposomes in a wide range of solvent systems. Experiments have shown that this liposome significantly enhances the stability and transdermal permeability of the encapsulated components, providing a universal, precise, and low-cost delivery platform for encapsulating various active ingredients.

The application discloses albumin site-directed modification lipid nanoparticles and preparation and application thereof, and relates to a kind of albumin site-directed modification lipid nanoparticles, which is prepared by synthesizing functionalized low molecular weight polyethylene glycol (PEG) lipid compound-maleimide derivative, together with the nucleic acid delivery lipid composition material usually used, to prepare nucleic acid-loaded lipid nanoparticles, then make the maleimide on its surface couple with the thiol group of albumin, to prepare the lipid nanoparticles with albumin site-directed modification on the surface.The application reduces the immunogenicity generated by the existing mRNA-loaded lipid nanoparticles outer layer covered PEG to the body, improves the related immune organ targeting of the nanoparticles, effectively delivers mRNA to lymph nodes to induce anti-tumor effect, and lays a foundation for further developing it as a new type of vaccine that can activate the immune system to produce anti-tumor effect.

A liposome of a nitrogen-containing heterocyclic compound comprises the following components: a nitrogen-containing heterocyclic compound as shown in compound 3 below and a lipid component. The liposomes of the present invention satisfy one or more of the following advantages: (1) small particle size and uniform distribution; (2) high API content; (3) high drug encapsulation efficiency; (4) good stability; (5) good antitumor activity; (6) good safety; and (7) long-lasting effect.

Process for coloring a lipid matrix blue from Ravenala madagascariensis arils. The invention relates mainly to a process for coloring a lipid matrix blue, which is essentially characterized in that it comprises at least the steps of: supplying or preparing a lipid matrix in liquid form; supplying or preparing seed arils of the plant species Ravenala madagascariensis; extracting the blue fat from the arils into the lipid matrix in liquid form, heated to a temperature between 40 and 60°C; and obtaining a blue-colored lipid composition. Depending on the nature of the lipid matrix used, the resulting lipid composition can be used in the cosmetic or food industries.

This invention discloses a method for detecting lipids in the embryo and endosperm of plant seeds, comprising the following steps: (1) separating the embryo and endosperm from the plant seeds; (2) freeze-drying the embryo and / or endosperm to remove free water; (3) grinding the embryo and endosperm into powder, extracting the embryo or endosperm powder with a first organic solution containing 2,6-di-tert-butyl-p-cresol (BHT), drying the extract to obtain a lipid extract, suspending the lipid extract in a second organic solution to obtain an LC-MS sample; (4) analyzing the sample using a liquid chromatography-mass spectrometry (LC-MS) instrument, processing the data, and determining the content of each lipid compound. The lipid composition of the embryo and endosperm obtained by this invention is accurate and reliable, and can be used for the evaluation of high-oil new germplasm.

The present invention addresses the problem of providing: an agent for delivering a nucleic acid to immune cells, which is capable of delivering a nucleic acid to both activated immune cells and non-activated immune cells; and a method for delivering a nucleic acid to immune cells using the agent for delivering a nucleic acid to immune cells. The present invention provides an agent for delivering a nucleic acid to immune cells, the agent comprising a lipid composition comprising: an ionizable lipid that is a compound represented by formula (1) or a salt thereof; a non-ionizable lipid; a lipid having a nonionic polymer; and a nucleic acid. In the formula, R1 to R9 are as defined in the description.

This invention relates to lipid compositions, pancreatic-targeting lipid nanoparticles, their preparation methods, and applications. The lipid composition comprises cationic lipids, cholesterol, phospholipids, and polyethylene glycol-modified lipids; the mass ratio of the cationic lipids, cholesterol, phospholipids, and polyethylene glycol-modified lipids is 16:7-20:4-12:2-4; the cationic lipids are obtained by reacting 3,7-dimethyl-6-octen-1-ylacrylate with polyethyleneimine. The pancreatic-targeting lipid nanoparticles are self-assembled from the lipid composition in an aqueous medium. The lipid nanoparticles of this invention exhibit excellent pancreatic tumor targeting ability, capable of delivering nucleic acid drugs (e.g., IL-12 mRNA) to in situ PDAC and other tumor tissues, significantly enhancing anti-tumor immune capacity, thereby significantly improving their therapeutic efficacy and safety against PDAC and other tumors.

The present disclosure provides a lipid nanoparticle wherein the lipid ingredient comprises a compound of formula (IV). The present disclosure also provides a method of preparing the lipid nanoparticle, a pharmaceutical composition of the lipid nanoparticle, and use of the lipid nanoparticle and pharmaceutical compositions in the delivery of nucleic acids.

This invention provides an ionizable cationic lipid compound, its preparation method, and its application, belonging to the field of biomedical technology. The ionizable cationic lipid compound provided by this invention is a compound having formula (1), or its salt, stereoisomer, or tautomer, and can be used as a surfactant in various fields, especially as a lipid composition for delivering therapeutic agents. The lipid nanoparticles prepared from it can exhibit good efficacy and safety in cells and animals.

According to one embodiment, a designing method for predicting a composition of a delivery carrier that satisfies a target value of an active agent delivery amount for a target cell is provided. The method includes preparing a delivery carrier prediction tool and acquiring, using the delivery carrier prediction tool, the composition of the delivery carrier that satisfies the target value based on a lipid composition of a cell membrane of the target cell.

Lipid compounds or pharmaceutically acceptable salts thereof are disclosed, said lipid compounds having the structure of formula (I): Formula (I), wherein the groups are as defined in this application. Nanoparticle compositions comprising the lipids of the invention capable of delivering therapeutic agents are also disclosed. This application further discloses pharmaceutical compositions comprising the lipid compositions of the invention. (I)

A lipid composition having the formula (1): wherein: R is a linear or branched hydrophobic group containing at least four carbon atoms and at least one linkage in which at least three carbon atoms are connected together, and wherein R optionally contains one or more heteroatoms selected from O, N, and S atoms; L is a bond or a linker containing 1-3 atoms, wherein at least one of the atoms is a heteroatom selected from O and N atoms; Ra, Rb, Rc, and Rd are independently selected from H, halogen, methyl group, halomethyl group, C≡N, hydroxy group, and methoxy group; and n is an integer of 1, 2, or 3. Also described herein are methods of producing LNPs in which the lipid composition of Formula (1) is incorporated and methods for delivering a therapeutic substance to a subject, such as an mRNA, by administering to the subject an LNP composition described above.

Disclosed are lipid nanoparticle formulations comprising a lipidoid as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses a pharmaceutical composition comprising a lipidoid composition of the invention.

Provided herein are polyglycerol conjugated lipid compounds that can be used in combination with other lipid components, such as cationic lipids, neutral lipids, and cholesterol, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes. Also provided herein are lipid nanoparticle compositions comprising said polymer conjugated lipid compounds.

The application belongs to the field of quality standards and detection technology of health food, and discloses a detection method for detecting the content of multiple lipid components in ganoderma lucidum spore oil by a multi-evaluation method. In the application, high performance liquid chromatography is used, glyceryl trioleate is used as an internal reference, correction factors of glyceryl trioleate and other lipid components are established, and the correction factors are used to calculate the concentrations of multiple to-be-measured components in the lipid. In the application, acetonitrile-acetone-isooctane is used as a mobile phase, and HPLC-UV is used in combination, and the specificity is strong.

Described herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic acids (e.g., circular polynucleotides), both in vitro and in vivo.

The disclosure relates to methods and compositions for assessing an immune response to a lipid composition using iMonocytes.

The present disclosure relates to compounds of the general formula (I):wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

The present invention relates to lipid comprising docosapentaenoic acid and / or docosahexaenoic acid wherein the docosapentaenoic acid and / or docosahexaenoic acid may be preferentially esterified at the sn-2 position of triacylglycerol, and processes for producing and using the lipid.

This invention discloses a lipid nanoparticle composition for encapsulating nucleic acids and a method for producing the same. In this composition, the ratio of empty lipid nanoparticles (those not encapsulating nucleic acids) to the total number of lipid nanoparticles, i.e., the empty particle rate, is 10% or less. By the production method of this invention, after the lipid nanoparticles have sufficiently fused, the morphology and structure of the particles become more uniform, and the particles become more stable. Compared to particles produced by conventional methods, the nucleic acid-containing lipid nanoparticles of this invention are essentially all effective particles that encapsulate nucleic acids, which is advantageous for improving nucleic acid delivery efficiency, reducing the risk of inflammatory adverse reactions due to lipid components, and improving the efficacy and safety of nucleic acid drugs.

There is provided a vegetable-based lipid composition comprising high levels of at least three different long-chain polyunsaturated fatty acids (typically as fatty acid esters). The compositions typically contain DHA as the principal long-chain polyunsaturated fatty acid. The composition is obtainable from a single source by conventional processing methods, and has improved stability properties.

A lipid composition includes, by weight of the lipid composition: from 30 wt % to 70 wt % a first lipid component; from 10 wt % to 40 wt % a sweetening substance; from 5 wt % to 20 wt % water; from 0.1 wt % to 1.2 wt % an emulsifier; and 1.5 wt % to 11 wt % a second lipid component. The emulsifier has a SFA content of less than 90 wt %. The second lipid component has a SFA content of at least 90 wt %, and fully saturated fatty acids with a carbon chain of more than 16 carbons account for at least 33.3 wt % of the SFA content of the second lipid component by weight. The molar amount of the second lipid component accounts for from 2.2 mol % to 15 mol % of the total molar amount of the first lipid component, the emulsifier and the second lipid component.